Lisa Coussens, Elliott Levy, Patricia LoRusso named to inaugural Shasqi scientific advisory board; Jean-Frédéric Viret, Mukul Agarwal named to leadership roles

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Shasqi Inc. a clinical stage biotech company, has established a scientific advisory board with leaders in oncology (The Cancer Letter, July 28, 2023). 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Positive high-level results from the POTOMAC phase III trial showed one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer compared to BCG induction and maintenance therapy alone.​

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login